Compare Mercadolibre Inc (MELI) vs Novartis AG (NVS) Price & Performance

Mercadolibre IncTrade

Novartis AGTrade

Price performance (Past 24H)

Key statistics

Mercadolibre Inc vs Novartis AG — how do they compare? Mercadolibre Inc trades at $1,930.02 (market cap $98.35B), while Novartis AG trades at $152.38 (market cap $295.37B). The key difference: Novartis AG is far larger — about 3× Mercadolibre Inc's market cap, and Novartis AG pays a 3.07% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals.

	MELI	NVS
Market Cap	$98.35B	$295.37B
Sector	Consumer Cyclical	Health
52-Week High	$2.51K	$168.62
52-Week Low	$1.55K	$119.31
Enterprise Value	$106.00B	$336.69B
Dividend Yield	—	3.07%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MELI

Sea Limited shares jump 13.8% after strong Q1 revenue growth and reinvestment strategy24/7 Wall Street · 22 hours agoBullish View details →

NVS

BioCryst hits profitability with strong Q2 revenue, sparking takeover interest in rare disease biotech.24/7 Wall Street · 1 day agoBullish View details →

About Mercadolibre Inc

MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.